Volume 48, Issue 7

Search all European Journal of Nuclear Medicine and Molecular Imaging articles

July 2021

Validity of imaging and fluid biomarkers of Alzheimer’s Disease neuropathology

Issue Editors:

Valentina Garibotto,
Giovanni B. Frisoni

19 articles in this issue

Molecular imaging and fluid biomarkers of Alzheimer’s disease neuropathology: an opportunity for integrated diagnostics
Valentina Garibotto
Marina Boccardi
Giovanni B. Frisoni
Editorial 10 March 2021 Pages: 2067 - 2069
Part of 1 collection:

Neurology – Dementia
The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update
Marina Boccardi
Alessandra Dodich
Valentina Garibotto
Original Article Open access 10 March 2021 Pages: 2070 - 2085
Part of 1 collection:

Neurology – Dementia
Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
Konstantinos Chiotis
Alessandra Dodich
Agneta Nordberg
Review Article Open access 15 March 2021 Pages: 2086 - 2096
Part of 1 collection:

Neurology – Dementia
Clinical validity of increased cortical uptake of [¹⁸F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
E. E. Wolters
A. Dodich
R. Ossenkoppele
Review Article Open access 06 February 2021 Pages: 2097 - 2109
Part of 1 collection:

Neurology
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
Gérard N Bischof
Alessandra Dodich
Alexander Drzezga
Review Article Open access 16 February 2021 Pages: 2110 - 2120
Part of 1 collection:

Neurology – Dementia
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
A. Leuzy
N. J. Ashton
O. Hansson
Review Article Open access 05 March 2021 Pages: 2121 - 2139
Part of 1 collection:

Neurology – Dementia
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
N. J. Ashton
A. Leuzy
O. Hansson
Review Article Open access 06 March 2021 Pages: 2140 - 2156
Part of 1 collection:

Neurology
Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives
Matteo Cotta Ramusino
Giulia Perini
Marina Boccardi
Review Article Open access 17 February 2021 Pages: 2157 - 2168
Part of 1 collection:

Neurology
Visual assessment of [¹⁸F]flutemetamol PET images can detect early amyloid pathology and grade its extent
Lyduine E. Collij
Gemma Salvadó
On behalf of the AMYPAD consortium
Original Article Open access 22 February 2021 Pages: 2169 - 2182
Part of 1 collection:

Neurology – Dementia
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [¹⁸F]flutemetamol amyloid PET images
Marco Bucci
Irina Savitcheva
Agneta Nordberg
Original Article Open access 12 April 2021 Pages: 2183 - 2199
Part of 1 collection:

Neurology – Dementia
Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
Daniele Altomare
Camilla Caprioglio
Valentina Garibotto
Original Article Open access 27 February 2021 Pages: 2200 - 2211
Part of 1 collection:

Translational research
Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia
Gemma Salvadó
Michel J. Grothe
for the Alzheimer’s Disease Neuroimaging Initiative
Original Article Open access 01 February 2021 Pages: 2212 - 2224
Part of 1 collection:

Neurology – Dementia
Relationship between amyloid and tau levels and its impact on tau spreading
Vincent Doré
Natasha Krishnadas
Christopher C. Rowe
Original Article Open access 26 January 2021 Pages: 2225 - 2232
Part of 1 collection:

Neurology – Dementia
Tau PET imaging with ¹⁸F-PI-2620 in aging and neurodegenerative diseases
Elizabeth C. Mormino
Tyler N. Toueg
Frederick T. Chin
Original Article 23 June 2020 Pages: 2233 - 2244
Part of 1 collection:

Neurology
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
Rik Ossenkoppele
Antoine Leuzy
Oskar Hansson
Original Article Open access 19 November 2020 Pages: 2245 - 2258
Part of 1 collection:

Neurology
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts
Karine Provost
Leonardo Iaccarino
For the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Original Article 04 January 2021 Pages: 2259 - 2271
Part of 1 collection:

Neurology – Dementia
Indication of retrograde tau spreading along Braak stages and functional connectivity pathways
Joseph Seemiller
Gérard N. Bischof
and the Alzheimer’s Disease Neuroimaging Initiative
Original Article 18 January 2021 Pages: 2272 - 2282
Part of 1 collection:

Neurology – Dementia
Reduced [¹⁸F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter
Alexis Moscoso
Michel J. Grothe
for the Alzheimer’s Disease Neuroimaging Initiative
Original Article 21 January 2021 Pages: 2283 - 2294
Part of 1 collection:

Neurology – Dementia
A multicenter comparison of [¹⁸F]flortaucipir, [¹⁸F]RO948, and [¹⁸F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
Antoine Leuzy
Tharick A. Pascoal
Oskar Hansson
Original Article Open access 27 May 2021 Pages: 2295 - 2305
Part of 1 collection:

Neurology – Dementia

Volume 48, Issue 7

Molecular imaging and fluid biomarkers of Alzheimer’s disease neuropathology: an opportunity for integrated diagnostics

The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

Clinical validity of increased cortical uptake of [¹⁸F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives

Visual assessment of [¹⁸F]flutemetamol PET images can detect early amyloid pathology and grade its extent

A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [¹⁸F]flutemetamol amyloid PET images

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison

Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia

Relationship between amyloid and tau levels and its impact on tau spreading

Tau PET imaging with ¹⁸F-PI-2620 in aging and neurodegenerative diseases

The impact of demographic, clinical, genetic, and imaging variables on tau PET status

Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts

Indication of retrograde tau spreading along Braak stages and functional connectivity pathways

Reduced [¹⁸F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter

A multicenter comparison of [¹⁸F]flortaucipir, [¹⁸F]RO948, and [¹⁸F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis

Navigation